Cogent Biosciences reports Q4/FY2023 net loss; $487M pro-forma cash; bezuclastinib trials on track

Cogent Biosciences, Inc.

Q4 2023 net loss $54.4M; FY2023 net loss $192.4M (up from $140.2M YoY); R&D expenses $173.8M for 2023.
Cash $273.2M at Dec 31, 2023; $225M PIPE closed Feb 2024 at $7.50/share (37% premium); pro-forma $487M funds into 2027.
Three registration-directed bezuclastinib trials enrolling: SUMMIT (NonAdvSM), APEX (AdvSM), PEAK (GIST); topline results expected in 2025.
SUMMIT Part 1b data: 51% mean TSS improvement, 70% of patients with ≥50% improvement; 100 mg RP2D selected.
PEAK lead-in: 33% confirmed ORR in 2nd-line GIST; bezuclastinib+sunitinib combination well-tolerated.

item 2.02 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.9

Cogent Biosciences, Inc. reported financial results for the quarter and year ended December 31, 2023.

Period: the quarter and year ended December 31, 2023
Result: reported results

Exact text from the filing

On February 26, 2024, Cogent Biosciences, Inc., a Delaware corporation (the “Company”), issued a press release announcing its financial results for the quarter and year ended December 31, 2023.

View on SEC.gov

Browse all earnings releases →

Cogent Biosciences, Inc. filing history →

Source: SEC EDGAR

accession 0000950170-24-019754

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.